Direct-to-tumor delivery system developer Surefire Medical said yesterday it brought in $15 million in a Series C round to support the global launch of its Surefire Precision device designed to treat primary liver cancer.
The round was led by Tullis Health Investors, and joined by KMG Capital Partners, Partisan Management Group, MCG partners, High Country Ventures and various angel investors, Westminster, Colo.-based Surefire Medical said.
“Tullis Health Investors looks forward to working with Surefire Medical on domestic and international commercial expansion, in particular the opportunity for Surefire in China. With more than 50% of global primary liver cancer cases occurring in China, the launch of the Precision is positioning Surefire to drive adoption by physicians performing embolization procedures, and may also help to decrease overall treatment costs,” Tullis Health Investors partner John Tullis said in a press release.
Surefire’s delivery systems are designed to deliver embolic agents through a microcatheter that expands and collapses during normal blood flow to deliver the agents as close to the tumor as possible, the company said.
“With the closing of this Series C financing and our collaboration with the Tullis team, we are launching our innovative and new Precision technology to physicians worldwide for treatment of primary liver cancers. The growing body of clinical evidence suggests that increasing the amount of therapeutic agents delivered into the tumor may improve patient response and overall survival. With the Surefire technology, more of the dose reaches the tumor while sparing healthy tissue,” Surefire Meidcal CEO James Chomas said in prepared remarks.
Surefire’s precision system has FDA approval in the U.S. and CE Mark approval in the European Union, and clearance in Canada, Australia, New Zealand, Taiwan, Mexico and Brazil, the company said.